The treatment landscape in thyroid cancer: a focus on cabozantinib
Steven P Weitzman, Maria E Cabanillas Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Abstract: Although patients with thyroid cancer generally fare well, there is a subset for which this is not necessarily true. Progress...
Main Authors: | Weitzman SP, Cabanillas ME |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2015-08-01
|
Series: | Cancer Management and Research |
Online Access: | http://www.dovepress.com/the-treatment-landscape-in-thyroid-cancer-a-focus-on-cabozantinib-peer-reviewed-article-CMAR |
Similar Items
-
Cabozantinib, Vandetanib, Pralsetinib and Selpercatinib as Treatment for Progressed Medullary Thyroid Cancer with a Main Focus on Hypertension as Adverse Effect
by: Linnea Højer Wang, et al.
Published: (2023-01-01) -
Cost-Effectiveness of Apatinib and Cabozantinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
by: Bo Shi, et al.
Published: (2022-06-01) -
Vandetanib versus Cabozantinib in Medullary Thyroid Carcinoma: A Focus on Anti-Angiogenic Effects in Zebrafish Model
by: Silvia Carra, et al.
Published: (2021-03-01) -
An Evaluation of Cabozantinib for the Treatment of Renal Cell Carcinoma: Focus on Patient Selection and Perspectives
by: Iaxx R, et al.
Published: (2022-06-01) -
Regression of Intracranial Meningiomas Following Treatment with Cabozantinib
by: Rupesh Kotecha, et al.
Published: (2021-04-01)